|Bid||0.9650 x 3000|
|Ask||1.2800 x 5000|
|Day's Range||0.9500 - 0.9995|
|52 Week Range||0.8800 - 2.0800|
|PE Ratio (TTM)||-0.86|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Company is engaged in developing efficient ways to fight cancer
At the beginning of 2015, Durham’s Heat Biologics (HTBX) announced a collaboration with San Diego-based biotechnology company OncoSec Medical Incorporated (ONCS). The companies announced this week that the collaboration – which is aimed at evaluating the delivery of immunotherapy vaccines being developed by Heat using OncoSec’s ImmunoPulse platform – is showing promise based on new preclinical data.
An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.